Solid Biosciences Inc. (SLDB)
NASDAQ
Market Cap
$126.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
403 of 951
Rank in Industry
243 of 544
Largest Insider Buys in Sector
SLDB Stock Price History Chart
SLDB Stock Performance
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Solid Biosciences Inc.
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $8,442 and sold $177,289 worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $26.42M and sold $273,262 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kahn Clare (director) — $8,442.
The last purchase of 1,100 shares for transaction amount of $8,442 was made by Kahn Clare (director) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Solid Biosciences Inc.
| 2025-01-10 | Sale | CFO & Treasurer | 4,073 0.0109% | $3.89 | $15,849 | 0.00% | ||
| 2025-01-06 | Sale | director | 1,056 0.0028% | $4.31 | $4,551 | -21.34% | ||
| 2024-12-03 | Sale | President and CEO | 11,114 0.0299% | $5.60 | $62,236 | -18.15% | ||
| 2024-12-03 | Sale | Chief Operating Officer | 5,072 0.0136% | $5.60 | $28,396 | -18.15% | ||
| 2024-12-03 | Sale | Chief Regulatory Officer | 4,610 0.0124% | $5.60 | $25,822 | -18.15% | ||
| 2024-12-03 | Sale | Chief Technology Officer | 2,777 0.0075% | $5.60 | $15,551 | -18.15% | ||
| 2024-10-21 | Sale | Chief Medical Officer | 2,923 0.0085% | $6.50 | $19,000 | -13.23% | ||
| 2024-06-07 | director | 1,100 0.0027% | $7.67 | $8,442 | -17.87% | |||
| 2024-05-02 | Sale | director | 462 0.0012% | $10.33 | $4,772 | -29.86% | ||
| 2024-01-29 | Sale | director | 139 0.0007% | $7.99 | $1,111 | +0.06% | ||
| 2024-01-11 | 3.41M 12.2033% | $5.53 | $18.86M | +0.89% | ||||
| 2024-01-11 | 904,160 3.235% | $5.53 | $5M | +0.89% | ||||
| 2024-01-09 | Sale | CFO & Treasurer | 3,935 0.0194% | $8.20 | $32,267 | -3.41% | ||
| 2024-01-03 | Sale | director | 1,142 0.0052% | $5.30 | $6,052 | +37.98% | ||
| 2023-12-04 | Sale | President and CEO | 11,757 0.0459% | $2.77 | $32,516 | +125.71% | ||
| 2023-12-04 | Sale | Chief Operating Officer | 5,367 0.0211% | $2.78 | $14,920 | +125.71% | ||
| 2023-12-04 | Sale | CSO | 4,890 0.0191% | $2.77 | $13,525 | +125.71% | ||
| 2023-12-04 | Sale | Chief Regulatory Officer | 4,879 0.0191% | $2.78 | $13,562 | +125.71% | ||
| 2023-12-04 | Sale | Chief Technology Officer | 2,968 0.0116% | $2.77 | $8,232 | +125.71% | ||
| 2023-05-02 | Sale | director | 487 0.0023% | $4.85 | $2,364 | +1.91% |
Insider Historical Profitability
<0.0001%
| Cumbo Alexander | President and CEO | 38484 0.0963% | $3.18 | 0 | 2 | |
| Tan Kevin | CFO & Treasurer | 24789 0.062% | $3.18 | 0 | 2 | |
| Howton David T | Chief Operating Officer | 15663 0.0392% | $3.18 | 0 | 2 | |
| Hanrahan Jessie | Chief Regulatory Officer | 14235 0.0356% | $3.18 | 0 | 2 | |
| Herzich Paul | Chief Technology Officer | 12182 0.0305% | $3.18 | 0 | 2 | |
| Ganot Ilan | director | 11445 0.0286% | $3.18 | 0 | 12 | |
| Brooks Gabriel | Chief Medical Officer | 10979 0.0275% | $3.18 | 0 | 1 | |
| Kahn Clare | director | 1100 0.0028% | $3.18 | 1 | 0 | |
| PERCEPTIVE ADVISORS LLC | 6833539 17.1033% | $3.18 | 4 | 0 | <0.0001% | |
| RA CAPITAL MANAGEMENT, L.P. | 4192216 10.4924% | $3.18 | 2 | 0 | <0.0001% | |
| Boxer Capital, LLC | 10 percent owner | 3473272 8.693% | $3.18 | 0 | 3 | |
| Arnold Matthew Bennett | director | 3386293 8.4754% | $3.18 | 0 | 2 | |
| Shah Rajeev M. | director | 2689444 6.7312% | $3.18 | 1 | 0 | |
| Koppel Adam | director | 1989444 4.9793% | $3.18 | 1 | 0 | |
| Ziolkowski Jennifer Lynn | CFO, Treasurer & Asst. Secy | 335636 0.84% | $3.18 | 0 | 2 | |
| Schneider Joel Solomon Zev | Chief Operating Officer | 251542 0.6296% | $3.18 | 0 | 5 | |
| Quiroz Jorge Armando | Chief Medical Officer | 228092 0.5709% | $3.18 | 0 | 2 | |
| HERSCHA LYNETTE | Chief Legal Officer | 160859 0.4026% | $3.18 | 0 | 1 | |
| Amorrortu Pedro Alvaro | Chief Operating Officer | 153746 0.3848% | $3.18 | 0 | 3 | |
| Morris Carl Ashley | Chief Scientific Officer | 19760 0.0495% | $3.18 | 0 | 5 | |
| Zarur Juan Andrey | director | 10189 0.0255% | $3.18 | 0 | 2 | |
| Marlowe Jennifer | CSO | 6998 0.0175% | $3.18 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Perceptive Advisors | $92M | 18 | 6.91M | +97.56% | +$45.43M | 0.06 | |
| RA Capital Management, L.P. | $57.68M | 11.28 | 4.33M | +26.39% | +$12.04M | 0.06 | |
| Bain Capital Life Sciences Investors Llc | $53.74M | 10.51 | 4.03M | +28.88% | +$12.04M | 4.32 | |
| Adage Capital Partners Gp L L C | $33.82M | 6.62 | 2.54M | New | +$33.82M | 0.06 | |
| Artal Group S A | $33.3M | 6.51 | 2.5M | +174.96% | +$21.19M | 0.15 | |
| Deerfield Management | $30.11M | 5.89 | 2.26M | New | +$30.11M | 0.07 | |
| Janus Henderson | $23.93M | 4.71 | 1.81M | New | +$23.93M | 0.01 | |
| Silverarc Capital Management Llc | $17.65M | 3.45 | 1.33M | +122.75% | +$9.73M | 0.18 | |
| The Vanguard Group | $16.58M | 3.24 | 1.24M | +283.93% | +$12.26M | <0.0001 | |
| FINEPOINT CAPITAL LP | $12.8M | 2.51 | 961,251 | 0% | +$0 | 2.06 | |
| Laurion Capital Management LP | $12.36M | 2.42 | 928,169 | 0% | +$0 | 0.09 | |
| Millennium Management LLC | $9.76M | 1.91 | 733,081 | New | +$9.76M | 0.01 | |
| Monashee Investment Management LLC | $8.26M | 1.62 | 620,000 | New | +$8.26M | 0.71 | |
| Walleye Capital | $7.68M | 1.5 | 576,267 | +362.64% | +$6.02M | 0.02 | |
| Invesco | $6.29M | 1.23 | 472,107 | New | +$6.29M | <0.01 | |
| Alyeska Investment Group L P | $5.52M | 1.08 | 414,615 | -34.94% | -$2.97M | 0.03 | |
| BlackRock | $4.09M | 0.8 | 307,066 | +169.13% | +$2.57M | <0.0001 | |
| Geode Capital Management | $3.17M | 0.62 | 237,673 | +154.19% | +$1.92M | <0.0001 | |
| Susquehanna International Group | $2.9M | 0.57 | 217,392 | +554.11% | +$2.45M | <0.01 | |
| Goldman Sachs | $2.71M | 0.53 | 203,748 | New | +$2.71M | <0.01 | |
| Qube Research & Technologies | $1.74M | 0.34 | 130,648 | New | +$1.74M | <0.01 | |
| Atom Investors Lp | $1.35M | 0.26 | 101,509 | New | +$1.35M | 0.09 | |
| Two Sigma | $1.16M | 0.23 | 87,388 | +134.93% | +$668,530.71 | <0.01 | |
| Jane Street Capital | $1.15M | 0.22 | 86,004 | New | +$1.15M | <0.01 | |
| State Street | $976,276.00 | 0.19 | 73,294 | +64.36% | +$382,283.97 | <0.0001 | |
| JPMorgan Chase | $936,090.00 | 0.18 | 70,277 | +52,739.85% | +$934,318.44 | <0.0001 | |
| Renaissance Technologies | $916,000.00 | 0.18 | 68,771 | +80.64% | +$408,910.73 | <0.01 | |
| Dimensional Fund Advisors | $872,993.00 | 0.17 | 65,540 | +31.21% | +$207,658.85 | <0.0001 | |
| Bridgeway Capital Management | $680,079.00 | 0.13 | 51,057 | 0% | +$0 | 0.01 | |
| Man Group Plc | $651,641.00 | 0.13 | 48,922 | New | +$651,641.00 | <0.01 | |
| Citigroup | $635,524.00 | 0.12 | 47,712 | New | +$635,524.00 | <0.0001 | |
| Northern Trust | $558,215.00 | 0.11 | 41,908 | +48.31% | +$181,831.46 | <0.0001 | |
| Marathon Trading Investment Management Llc | $496,836.00 | 0.1 | 37,300 | New | +$496,836.00 | 0.1 | |
| Citadel Advisors LLC | $458,541.00 | 0.09 | 34,425 | New | +$458,541.00 | <0.0001 | |
| Bank of America | $404,409.00 | 0.08 | 30,361 | +666.89% | +$351,675.06 | <0.0001 | |
| American Century Investments | $329,057.00 | 0.06 | 24,704 | New | +$329,057.00 | <0.0001 | |
| ExodusPoint Capital Management, LP | $321,000.00 | 0.06 | 24,085 | New | +$321,000.00 | <0.01 | |
| Balyasny Asset Management Llc | $313,353.00 | 0.06 | 23,525 | New | +$313,353.00 | <0.01 | |
| Morgan Stanley | $295,507.00 | 0.06 | 22,185 | +424.1% | +$239,122.91 | <0.0001 | |
| Two Sigma Advisers LP | $193,140.00 | 0.04 | 14,500 | New | +$193,140.00 | <0.0001 | |
| UBS | $189,797.00 | 0.04 | 14,249 | +254.1% | +$136,197.23 | <0.0001 | |
| Raymond James Financial Services Advisors Inc | $176,610.00 | 0.04 | 13,259 | New | +$176,610.00 | <0.0001 | |
| Charles Schwab | $136,876.00 | 0.03 | 10,276 | New | +$136,876.00 | <0.0001 | |
| Barclays | $59,000.00 | 0.01 | 4,417 | 0% | +$0 | <0.0001 | |
| LAZARD ASSET MANAGEMENT LLC | $21,000.00 | <0.01 | 1,629 | New | +$21,000.00 | <0.0001 | |
| Macquarie Group | $17,000.00 | <0.01 | 1,267 | New | +$17,000.00 | <0.0001 | |
| Advisor Group Holdings Inc | $399.00 | <0.01 | 30 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 66 | -97.84% | -$45,363.64 | <0.0001 | |
| First Manhattan Co. | $1,771.00 | <0.01 | 133 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $2,184.00 | <0.01 | 164 | +118.67% | +$1,185.22 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.